The Goldman Sachs Group Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $198.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective boosted by The Goldman Sachs Group from $174.00 to $198.00 in a research note published on Friday, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on the stock. Chardan Capital reissued a buy rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an overweight rating in a research report on Friday. Needham & Company LLC boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a buy rating in a research report on Friday. StockNews.com raised shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 29th. Finally, Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a buy rating in a research report on Friday. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $269.32.

Alnylam Pharmaceuticals Trading Down 2.6 %

ALNY opened at $265.00 on Friday. The stock has a market capitalization of $33.52 billion, a P/E ratio of -98.88 and a beta of 0.37. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $274.93. The firm’s fifty day simple moving average is $211.34 and its 200 day simple moving average is $175.01.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.21) earnings per share. On average, equities research analysts predict that Alnylam Pharmaceuticals will post -3.99 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,829,070. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,598 shares of company stock worth $19,377,944. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ALNY. Raymond James & Associates boosted its holdings in Alnylam Pharmaceuticals by 15.1% in the 4th quarter. Raymond James & Associates now owns 14,286 shares of the biopharmaceutical company’s stock valued at $2,734,000 after purchasing an additional 1,875 shares during the period. Ballentine Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $234,000. Arizona State Retirement System lifted its holdings in shares of Alnylam Pharmaceuticals by 1.1% during the 4th quarter. Arizona State Retirement System now owns 34,356 shares of the biopharmaceutical company’s stock worth $6,576,000 after acquiring an additional 383 shares during the period. Quilter Plc bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $255,000. Finally, Asset Management One Co. Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 41.3% during the 4th quarter. Asset Management One Co. Ltd. now owns 69,334 shares of the biopharmaceutical company’s stock worth $13,569,000 after acquiring an additional 20,268 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.